Literature DB >> 6821846

Multicentric giant follicular lymph node hyperplasia. Favorable response to radiotherapy.

S Marti, A Pahissa, J Guardia, A Moragas, R Bacardi.   

Abstract

Angiofollicular lymph node hyperplasia is a disease of unknown etiology in which two distinct histologic forms are recognized: the hyalin vascular and the plasma-cell types. Up to the current time only a few multicentric cases have been described. The authors describe an unusual case of the multicentric type, which furthermore showed an excellent response to low dosis radiotherapy. Complete, lasting remission was induced and the patient became asymptomatic.

Entities:  

Mesh:

Year:  1983        PMID: 6821846     DOI: 10.1002/1097-0142(19830301)51:5<808::aid-cncr2820510510>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Castleman's disease in childhood: report of three cases and review of the literature.

Authors:  Piero Farruggia; Antonino Trizzino; Nunzia Scibetta; Giovanni Cecchetto; Patrizia Guerrieri; Emanuele S G D'Amore; Paolo D'Angelo
Journal:  Ital J Pediatr       Date:  2011-10-20       Impact factor: 2.638

2.  Castleman's disease of the mesorectum: report of a case.

Authors:  Mi Ri Hwang; Hee Jin Chang; Min Ju Kim; Guh Jung Seo; Sang Bum Yoo; Ji Won Park; Hyo Seong Choi; Jae Hwan Oh
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

Review 3.  Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.

Authors:  Iris A C de Vries; Marjolein M S van Acht; Thomas B J Demeyere; Marnix L M Lybeert; Jean-Paul de Zoete; Grard A P Nieuwenhuijzen
Journal:  Radiat Oncol       Date:  2010-02-02       Impact factor: 3.481

4.  The clinical spectrum of Castleman's disease.

Authors:  Angela Dispenzieri; James O Armitage; Matt J Loe; Susan M Geyer; Jake Allred; John K Camoriano; David M Menke; Dennis D Weisenburger; Kay Ristow; Ahmet Dogan; Thomas M Habermann
Journal:  Am J Hematol       Date:  2012-07-13       Impact factor: 10.047

5.  Cases report of unicentric Castleman's disease: revisit of radiotherapy role.

Authors:  O Kyu Noh; Sang-Wook Lee; Jae Whan Lee; Sang Yoon Kim; Chung Soo Kim; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn
Journal:  Radiat Oncol J       Date:  2013-03-31

6.  Embolization of blood-supply artery followed by surgery for treatment of mesorectal Castleman's disease: case report and literature review.

Authors:  Guanyu Yu; Fuao Cao; Haifeng Gong; Peng Liu; Ge Sun; Wei Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-01-05

7.  Osteosarcoma Manifesting Systemic Inflammation and Histological Features Mimicking Plasma Cell-type Castleman Disease.

Authors:  Shino Fujimoto; Tomoyuki Sakai; Hiroshi Kawabata; Nozomu Kurose; Sohsuke Yamada; Mariko Doai; Munetaka Matoba; Haruka Iwao-Kawanami; Takafumi Kawanami; Shuichi Mizuta; Toshihiro Fukushima; Hiroki Mizumaki; Masaki Yamaguchi; Yasufumi Masaki
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

8.  Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature.

Authors:  Chance Matthiesen; Rajeev Ramgopol; Jonathan Seavey; Salahuddin Ahmad; Terence Herman
Journal:  Radiol Oncol       Date:  2012-01-02       Impact factor: 2.991

Review 9.  Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome.

Authors:  Hongbei Wang; Rosemary L Wieczorek; Michael E Zenilman; Fidelina Desoto-Lapaix; Bimal C Ghosh; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2007-11-20       Impact factor: 2.754

10.  Retroperitoneal Castleman's disease: advocating a multidisciplinary approach for a rare clinical entity.

Authors:  Austin D Williams; Adriana Sanchez; Jun Steve Hou; Rene Rothstein Rubin; Mark E Hysell; Blake D Babcock; Mohammad F Shaikh; Michael S Weingarten; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2014-02-04       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.